Dyadic國際 DYAI 深 滬
已收盤 07-02 16:00:00 美东时间
0.9405
-0.079
-7.79%
華盛通- 最 高1.00
- 今 開0.9961
- 成交量 9.74万股
- 最 低 0.9163
- 昨 收 1.02
- 總市值 3427.06万
- 52周最高 1.346
- 市盈率 靜 --
- 換手率 0.27%
- 52周最低 0.6546
- 委 比 -72.43%
- 總股本 3643.87万
- 歷史最高 10.98
- 量 比 0.31
- 振 幅 8.21%
- 歷史最低 0.6546
- 每 手 1
- 風險率 0.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dyadic Announces Japan Patent Office Allowance Of Claims Covering Its Proprietary Thermothelomyces Heterothallica Recombinant Protein Expression Technology
The Japan Patent Office allowed claims covering novel aspects of Dyadic’s proprietary Thermothelomyces heterothallica recombinant protein expression technology. This milestone adds significant protection to the Company’s expanding global intellectual property portfolio and reinforces the strength of...
06-29 19:27
Dyadic Expands IP Protection and Business Development Activities in Japan
Dyadic International announced that the Japan Patent Office has approved claims for its proprietary *Thermothelomyces heterothallica* recombinant protein expression technology, strengthening its intellectual property portfolio and strategic platforms. The company, which focuses on scalable microbial protein production, is expanding its presence in Japan through collaborations with Intralink, targeting key sectors like biotechnology, pharmaceutica...
06-29 11:25
Dyadic International shareholders approve reverse stock split authorization
Dyadic International shareholders approve reverse stock split authorization Dyadic International held its annual shareholder meeting on June 18, 2026. Shareholders backed authorization for the board to proceed with a reverse stock split at its discretion; no split was confirmed as executed. Sharehol
06-22 20:31
Dyadic Highlights Increasing Interest In Proprietary C1 Protein Production Platform As Global Infectious Disease Preparedness Efforts Intensify In Response To Ongoing Bundibugyo Ebola Virus Outbreak
Dyadic International, Inc. (NASDAQ:DYAI), d/b/a Dyadic Applied BioSolutions ("Dyadic" or the "Company"), a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms, today highlighted increasing interest in its proprietary C1 protein pr...
06-15 19:32
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
06-06 02:24
Dyadic's Applied Biosolutions Unit Collaborates With Scripps Research To Evaluate Monoclonal Antibody And Vaccine Candidates Targeting Hantaviruses, Including Andes Virus
A series of recently reported hantavirus and Ebola cases worldwide have underscored the importance of pandemic preparedness and highlighted the need to improve the speed, scalability, flexibility, and cost-effectiveness
05-28 19:29
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Akari Therapeutics (NASDAQ:AKTX) stock increased by 40.3% to $7.21 dur...
05-22 05:06
Dyadic COO Hazelton presents at Sidoti Virtual Investor Conference
Dyadic COO Hazelton presents at Sidoti Virtual Investor Conference Dyadic International will present at Sidoti’s Virtual Investor Conference on May 20, 2026 at 10:00 a.m. ET. Management will hold virtual one-on-one investor meetings during the May 20-21, 2026 conference window. Disclaimer: This news
05-19 21:35
Dyadic International Earnings Call Highlights Early Momentum
Dyadic International Inc. (($DYAI)) has held its Q1 earnings call. Read on for ...
05-15 08:39
Transcript: Dyadic International Q1 2026 Earnings Conference Call
Dyadic International (NASDAQ:DYAI) reported first-quarter financial results on ...
05-14 05:54
